Home

Senores Pharmaceuticals Ltd PE Ratio

Image

Senores Pharmaceuticals Ltd

NSE: SENORES

PE

78.1

Last updated on: Feb 05, 2025

Key Highlights

  • The P/E Ratio of Senores Pharmaceuticals Ltd is 78.1 as of 05 Feb 15:25 PM .
  • The P/E Ratio of Senores Pharmaceuticals Ltd changed from 0 on March 2022 to 0 on March 2024 . This represents a CAGR of 0.0% over 3 years.
  • The Latest Trading Price of Senores Pharmaceuticals Ltd is ₹ 548.75 as of 05 Feb 15:19 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 36.9 in 2024.

Historical P/E Ratio of Senores Pharmaceuticals Ltd

No data available

Company Fundamentals for Senores Pharmaceuticals Ltd

Image

Senores Pharmaceuticals Ltd

NSE: SENORES

Share Price

₹ 548.75

14.45 (2.70%)

stock direction

Last updated on: Feb 05, 2025

Market Price of Senores Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Senores Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
04 Feb 2025534.3
03 Feb 2025511.7
01 Feb 2025535.05
31 Jan 2025549.1
30 Jan 2025539.15
29 Jan 2025513.75
28 Jan 2025502.55
27 Jan 2025507.65
24 Jan 2025560.7
23 Jan 2025543.3

BlinkX Score for Senores Pharmaceuticals Ltd

Asset Value vs Market Value of Senores Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Competitive Comparison of P/E Ratio

Company
leftMarket Capright
Senores Pharmaceuticals Ltd2460
Sun Pharmaceuticals Industries Ltd423975
Divis Laboratories Ltd161729
Cipla Ltd116999
Mankind Pharma Ltd105258
Torrent Pharmaceuticals Ltd105084

PE Ratio of Senores Pharmaceuticals Ltd Explained

2460

Market cap

40

Earnings

78.1X

PE Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Senores Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Senores Pharmaceuticals Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Historical Dividend Payout of Senores Pharmaceuticals Ltd

No data available

* All values are in %

About Senores Pharmaceuticals Ltd

  • Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.
  • Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
  • The Regulated Markets business is focused on Regulated Markets of US and Canada.
  • The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs.

Senores Pharmaceuticals Ltd News Hub

Senores Pharma spurts as PAT jumps to Rs 16 cr in Q3 FY25

Profit before tax stood at Rs 20.48 crore in the December 2024 quarter, up 99.61% from Rs 10.26 cror

Read more

23 Jan 25

Senores Pharma gets final approval for Metoprolol Tartrate and Hydrochlorothiazide tablets

Metoprolol Tartrate and Hydrochlorothiazide Tablet is the combination tablet of metoprolol tartrate,

Read more

10 Jan 25

Senores Pharmaceuticals IPO subscribed 93.41 times

The initial public offer (IPO) of Senores Pharmaceuticals received bids for 79,72,30,918 shares as a

Read more

24 Dec 24

Senores Pharmaceuticals receives USFDA approval for Metoprolol Tartrate and Hydrochlorothiazide Tablet

Senores Pharmaceuticals has received final approval from the United States Food and Drug Administrat

Read more

10 Jan 25

Product Composition by Percentage (Revenue)

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Senores Pharmaceuticals Ltd

What is the current PE Ratio of Senores Pharmaceuticals Ltd?

The Current PE Ratio of Senores Pharmaceuticals Ltd is 78.11 as on 5 Feb 2025.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 5 Feb 2025.

What was the PE Ratio of Senores Pharmaceuticals Ltd last year?

The PE Ratio of Senores Pharmaceuticals Ltd was 0.0 last year, now the PE ratio is 78.11, showing a year-on-year growth of -%.

What does the PE Ratio of Senores Pharmaceuticals Ltd indicate about its stock?

The PE Ratio of Senores Pharmaceuticals Ltd is 78.11. This ratio indicates that investors are willing to pay 78.11 times the earnings per share for each share of Senores Pharmaceuticals Ltd.

What is the PE Ratio Growth of Senores Pharmaceuticals Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Senores Pharmaceuticals Ltd grew by -% whereas, the EPS ratio grew by -3.4.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions